Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation

Nature Medicine

Volumn 6, Issue 11, 2000, Pages 1253-1257

  Rothbard, Jonathan B ^a   Garlington, Sarah ^a   Lin, Qun ^b,c   Kirschberg, Thorsten ^a   Kreider, Erik ^a   McGrane, P Leo ^a   Wender, Paul A ^d   Khavari, Paul A ^b,c  

^a Cellgate Incorporated   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; CARRIER PROTEIN; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOTINYLATION; CONTACT DERMATITIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG PENETRATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFLAMMATION; SKIN PERMEABILITY; T LYMPHOCYTE;

ADMINISTRATION, TOPICAL; ANIMALS; ARGININE; BIOLOGICAL TRANSPORT; BIOTINYLATION; CYCLOSPORINE; CYCLOSPORINS; HUMANS; INFLAMMATION; INTERLEUKIN-2; IONOMYCIN; JURKAT CELLS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PRODRUGS; SKIN; SKIN ABSORPTION; TETRADECANOYLPHORBOL ACETATE;

ANIMALIA;

EID: 0033678653     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/81359     Document Type: Article

References (38)

1. Targeted drug delivery to the skin and deeper tissues: Role of physiology, solute structure and disease
2. Drug delivery systems. 6. Transdermal drug delivery
3. The selection and design of topical and transdermal agents: A review
4. Transcutaneous drug delivery: A practical review
5. Percutaneous penetration enhancement and its quantification
6. Sphingolipid activator proteins are required for epidermal permeability barrier formation
7. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model
8. Barrier function regulates epidermal lipid and DNA synthesis
9. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
10. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
11. Cyclosporin in atopic dermatitis: Review of the literature and outline of a Belgian consensus
12. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: A 1-year multicentre, randomized study. The PISCES Study Group
13. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group
14. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996
15. Renal function after 10 years' treatment with cyclosporin for psoriasis
16. Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis
17. Topical cyclosporin in oral lichen planus: A controlled, randomized, prospective trial
18. Immunomodulation of psoriasis with a topical cyclosporin A formulation
19. Effect of a new topical cyclosporin formulation on human allergic contact dermatitis
20. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis
21. Topical cyclosporin A in alopecia areata
22. Placebo-controlled trial of topical cyclosporin in severe alopecia areata
23. The enigma of cyclosporin A treatment for psoriasis: Systemic efficacy versus topical non-responsiveness. A review
24. Penetration of sandimmune (cyclosporin A) in rat skin in vitro. Effects of penetration enhancers and solvents
25. The molecular basis of glucocorticoid-induced skin atrophy: Topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo
26. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations
27. Adrenal axis suppression caused by a small dose of a potent topical corticosteroid
28. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
29. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p 27Kip1 induces cell migration
30. The third helix of the antennapedia homeodomain translocates through biological membranes
31. Protein transduction: Unrestricted delivery into all cells?
32. Dimerization as a regulatory mechanism in signal transduction
33. Cyclophilin: A specific cytosolic binding protein for cyclosporin A
34. Activation of a human T cell line: A two-stimulus requirement in the pretranslational events involved in the coordinate expression of interleukin 2 and gamma-interferon genes
35. Corrective gene transfer in the human skin disorder lamellar ichthyosis
36. Messenger proteins: Homeoproteins, TAT and others
37. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry